Provenge Review In 2008 Hinges On IMPACT Interim Analysis
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will accept positive interim analysis of survival from the Phase III trial for registration of the therapeutic cancer vaccine, Dendreon confirms.
You may also be interested in...
Life Beyond Provenge: Dendreon Plans To Move First Small Molecule Into The Clinic
While Dendreon awaits data to complete the prostate cancer vaccine’s BLA, other candidates progress.
House Panel Denies Members' Request To Investigate Provenge Advisory Committee
Bipartisan group looking to investigate conflict of interest at an FDA advisory committee on Provenge were stopped in their tracks by a letter from Energy & Commerce Committee leaders.
Life Beyond Provenge: Dendreon Plans To Move First Small Molecule Into The Clinic
While Dendreon awaits data to complete the prostate cancer vaccine’s BLA, other candidates progress.